Clinical Report: Utilizing Oxford Classification Activity Scores to Direct Immunotherapy in IgA Nephropathy

Overview

This study investigates the role of Oxford classification activity scores in guiding immunotherapy for IgA nephropathy. It finds that immunotherapy is associated with a 22% increase in proteinuria remission at 12 months (HR 1.22; 95% CI 1.07-1.40; p=0.004), particularly in patients with high SumMEC scores.

Background

IgA nephropathy is the most common primary glomerulonephritis, accounting for a significant proportion of glomerulonephritis cases. The Oxford classification system has been proposed as a prognostic tool, but its utility in directing immunotherapy remains debated. Understanding the relationship between histological features and treatment response is crucial for optimizing patient management.

Data Highlights

A total of 2,389 patients were analyzed, with 1,211 receiving immunosuppressive therapy. Immunotherapy was associated with a 22% increase in proteinuria remission at 12 months (HR 1.22; 95% CI 1.07-1.40; p=0.004).

Key Findings

• Immunotherapy improved proteinuria remission in IgA nephropathy patients.
• High SumMEC scores were associated with better responses to immunotherapy.
• Multivariate analysis indicated a 22% increase in remission rates at 12 months with immunotherapy.
• Subgroup analyses showed comparable effects on 6-month and 12-month remission rates.

Clinical Implications

Clinicians should consider the findings regarding SumMEC scores when making treatment decisions for IgA nephropathy.

Conclusion

Immunosuppressive therapy may enhance proteinuria remission in patients with IgA nephropathy, particularly those with high SumMEC scores.

Related Resources & Content

1. KDIGO, KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV), 2025 -- KDIGO 2025 Clinical Practice Guideline
2. Clinical Rheumatology, A straightforward machine learning-based scoring system forecasts resistance to intravenous immunoglobulin in Kawasaki disease, 2023 -- A straightforward machine learning-based scoring system forecasts resistance to intravenous immunoglobulin in Kawasaki disease
3. Evaluating Prognostic Models for Overall Survival in Patients with Metastatic Renal and Urothelial Cancers Treated with Immunotherapy: Which Model Should Be Selected?, 2025 -- Evaluating Prognostic Models for Overall Survival in Patients with Metastatic Renal and Urothelial Cancers Treated with Immunotherapy
4. Retinal Physician — Standardizing Ocular Toxicity Grading for ADCs
5. Clinical Rheumatology — Streamlining the Classification of ANCA-Associated Vasculitis Based on ANCA Specificity: A Retrospective Study
6. KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)
7. The Pathology of IgA Nephropathy: How Can It Inform Management? - ScienceDirect